Et al: The mitochondrial complex I inhibitor rotenone triggers a cerebral tauopathy. J Neurochem 2005,

Et al: The mitochondrial complex I inhibitor rotenone triggers a cerebral tauopathy. J Neurochem 2005, 95(4):930-939. 50. Lyamzaev KG, Izyumov DS, Avetisyan AV, Yang F, Pletjushkina OY, Chernyak BV: Inhibition of mitochondrial bioenergetics: the effects on structure of mitochondria in the cell and on apoptosis. Acta Biochim Pol 2004, 51(2):553-562. 51. Bai J, Nakamura H, Ueda S, Kwon YW, Tanaka T, Ban S, Yodoi J: Proteasome-dependent degradation of cyclin D1 in 1-methyl-4phenylpyridinium ion (MPP+)-induced cell cycle arrest. J Biol Chem 2004, 279(37):38710-38714. Pre-publication history The pre-publication history for this paper can be accessed here: Cite this article as: Lee et al.: Squamocin modulates histone H3 phosphorylation levels and induces G1 phase arrest and apoptosis in cancer cells. BMC Cancer 2011 11:58.Submit your next manuscript to BioMed Central and take full advantage of:?Convenient online submission ?Thorough peer review ?No space constraints or color figure charges ?Immediate publication on acceptance ?Inclusion in PubMed, CAS, Scopus and Google Scholar ?Research which is freely available for redistributionSubmit your manuscript at
Blesius et al. BMC Cancer 2011, 11:72 ARTICLEOpen AccessNeoadjuvant imatinib in patients with locally advanced non metastatic GIST in the prospective BFR14 trialAurore Blesius1, Philippe A Cassier2*, Fran is Bertucci3, Jerome Fayette2, Isabelle Ray-Coquard2, Binh Bui4, Antoine Adenis5, Maria Rios6, Didier Cupissol7, David P ol8, Jean-Yves Blay2, Axel Le CesneAbstractBackground: The role of surgery in the management of patients with advanced gastrointestinal stromal tumors (GIST) in the era of imatinib mesylate (IM) remains debated. We analyzed the outcome of patients with PubMed ID: non metastatic locally advanced primary GIST treated with IM within the prospective BFR14 phase III trial. Methods: The database of the BFR14 trial was searched for patients with no metastasis at time of inclusion. Patients treated for recurrent disease were excluded. Twenty-five of 434 patients met these criteria. Results: Fifteen of 25 patients (60 ) had a partial response to IM. Nine of the 25 patients (36 ) underwent surgical resection of their primary tumor after a median of 7.3 months of IM treatment (range 3.4-12.0). Per protocol patients received continuous IM treatment in the post resection period, in an adjuvant setting. With a median follow-up of 53.5 months, there was a significant improvement in progression-free survival (PFS) and overall survival (OS) for patients who underwent surgical resection versus those who did not (median not reached vs 23.6 months, p = 0.0318 for PFS and median not reached vs 42.2 months, p = 0.0217 for OS). In the group of patients who underwent resection followed by IM, the 3-year PFS and OS rates were 67 and 89 respectively Conclusions: Following neoadjuvant IM for non metastatic locally advanced GIST 9 of 25 patients (36 ) were selected for resection of the primary tumor. OS and PFS figures were close to those of localised intermediate or high risk GIST (70 at 5 years) in the order BL-8040 subgroup of operated patients, while the outcome of the non-operated subgroup was similar to that of metastatic GIST.Background Gastrointestinal stromal tumors (GIST) are the most frequent mesenchymal tumors of the gastrointestinal tract and are thou.